Related Experiment Videos
R-(-)-deprenyl and parkinsonism
1Department of Neurology, Mt. Sinai School of Medicine, City University of New York, New York City.
Journal of Neural Transmission. Supplementum
|January 1, 1987
Summary
L-deprenyl effectively inhibits MAO-B, an enzyme implicated in Parkinson's disease. When added to levodopa therapy, it helps manage motor fluctuations, potentially slowing disease progression.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Neurology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Levodopa is a primary treatment, but motor fluctuations are common.
- Monoamine oxidase B (MAO-B) inhibitors are used in PD management.
Purpose of the Study:
- To evaluate the efficacy and safety of L-deprenyl in Parkinson's disease.
- To assess L-deprenyl's role in managing levodopa-induced motor fluctuations.
- To explore L-deprenyl's potential neuroprotective effects.
Main Methods:
- Clinical trials involving patients with Parkinson's disease.
- Administration of L-deprenyl at a daily dosage of 10 mg.
- Combination therapy with levodopa and L-deprenyl.
Main Results:
- L-deprenyl monotherapy does not control Parkinson's disease symptoms.
- L-deprenyl addition to levodopa attenuates or controls "wearing off" fluctuations.
- Potential for increased life expectancy and halting nigro-striatal degeneration suggested.
Conclusions:
- L-deprenyl is a safe and well-tolerated MAO-B inhibitor.
- L-deprenyl is effective in managing motor fluctuations in Parkinson's disease patients on levodopa.
- Early L-deprenyl treatment may offer neuroprotective benefits, warranting further investigation.